About company
VIVA Pharm
One of the leaders in the field of pharmaceutical development, clinical research, registration, production, storage and distribution of a wide range of high-quality and affordable medicines for patients.
We are in numbers
Employees in company
International partners
Years of experience in the pharmaceutical market
Own production
Partnership
Critical to a company's success
Our close ties with global pharmaceutical manufacturers allow us to be at the forefront of the global drug market, as well as provide the best drugs and medical products to consumers in Kazakhstan and other countries of the region.
Geography and
presence
VIVA Pharm medicines are available in Kazakhstan, as well as in Uzbekistan, Kyrgyzstan and Russia.
Сountries
Regions
Сities of republican significance
News
Amlodipine Viva Pharm
17 June 2022VIVA PHARM in cooperation with the Center of Nuclear Medicine and Oncology in Semey, has successfully completed a clinical trial of a medication.
“B.A.Mashkeev grant”
1 April 2022In February 2022 the founder of the company VIVA Pharm, Batyrbek Aukenovich Mashkeev
VIVA Pharm - opening new horizons...
10 September 2021VIVA Pharm is one of the leaders in the field of pharmaceutical development, clinical
Рабочий визит акима г. Алматы Бакытжана Сагинтаева на предприятие ТОО «ВИВА ФАРМ»
16 July 2021VIVA Pharm — один из лидеров в области фармацевтической разработки, клинических
VIVA Pharm is the best employer of the year in health care
30 April 2021VIVA Pharm — один из лидеров в области фармацевтической разработки, клинических
Obtaining a GDP Certificate
26 May 2020 Detail
VIVA Pharm is with you! Be healthy!
24 April 2020 Detail
Cardiovascular Prevention 2019: from Clinical Case to Recommendations
16 October 2019On October 10-11, 2019, the II Republican Congress on Arterial Hypertension and Cardiovascular Prevention with international participation was held in Almaty.
GMP Certificate
10 July 2018 Detail
Extension of Accreditation Scope of Our Testing Laboratory
10 July 2018 Detail
The place of sartans in the therapy of arterial hypertension and chronic heart failure.
31 March 2018 Detail
